Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Holdings Decreased by Wellington Management Group LLP

Wellington Management Group LLP lowered its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 18.8% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,017,647 shares of the biopharmaceutical company's stock after selling 235,257 shares during the quarter. Wellington Management Group LLP owned approximately 0.96% of Intra-Cellular Therapies worth $74,461,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of ITCI. True Wealth Design LLC purchased a new position in shares of Intra-Cellular Therapies during the third quarter valued at approximately $32,000. Summit Securities Group LLC purchased a new position in shares of Intra-Cellular Therapies during the 2nd quarter worth $56,000. Capital Performance Advisors LLP acquired a new stake in shares of Intra-Cellular Therapies during the third quarter worth $74,000. CWM LLC grew its position in shares of Intra-Cellular Therapies by 83.9% in the second quarter. CWM LLC now owns 1,372 shares of the biopharmaceutical company's stock valued at $94,000 after purchasing an additional 626 shares during the period. Finally, Quarry LP increased its stake in Intra-Cellular Therapies by 260.0% in the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock valued at $132,000 after purchasing an additional 1,300 shares during the last quarter. Institutional investors and hedge funds own 92.33% of the company's stock.

Intra-Cellular Therapies Stock Performance

Shares of NASDAQ:ITCI traded up $0.77 during mid-day trading on Wednesday, hitting $83.88. 434,441 shares of the company traded hands, compared to its average volume of 832,255. The firm has a market cap of $8.89 billion, a P/E ratio of -95.53 and a beta of 0.95. Intra-Cellular Therapies, Inc. has a 52-week low of $58.92 and a 52-week high of $93.45. The firm's 50 day simple moving average is $81.78 and its 200 day simple moving average is $76.47.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.07). The firm had revenue of $175.40 million for the quarter, compared to analyst estimates of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company's revenue for the quarter was up 39.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.25) earnings per share. Equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Insider Buying and Selling at Intra-Cellular Therapies

In other news, President Michael Halstead sold 22,869 shares of the firm's stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total transaction of $2,038,085.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares of the company's stock, valued at approximately $91,834,228.20. This trade represents a 4.55 % decrease in their position. The disclosure for this sale can be found here. 2.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on ITCI. Morgan Stanley lifted their price target on Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an "overweight" rating in a report on Friday, October 11th. Royal Bank of Canada boosted their target price on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an "outperform" rating in a report on Friday, October 4th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $130.00 price target on shares of Intra-Cellular Therapies in a research note on Monday, September 16th. Piper Sandler raised shares of Intra-Cellular Therapies from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $68.00 to $92.00 in a research note on Friday, September 6th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $100.00 target price on shares of Intra-Cellular Therapies in a research report on Wednesday, October 30th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $97.23.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.